{"success":true,"data":{"pressRelease":{"id":"156410","rtpr_id":"nBw5rCST0a-20260930","ticker":"KVUE","exchange":"NYSE","all_tickers":["KVUE"],"title":"Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair","author":"Business Wire","published_at":"2026-09-30T10:45:00.172Z","article_body":"Neutrogena(®), Aveeno(®), and Regaine(®) Present New Scientific Evidence\nDemonstrating How Science-Backed Ingredients Support Healthy Skin and Hair\n\nResearch shared at the 35th European Academy of Dermatology and Venereology\n(EADV) Congress highlights the benefits of multifunctional sunscreens,\ncolloidal oat formulations addressing acne, hyperpigmentation, eczema,\nUV-related skin damage, and the impact of 5% minoxidil for alopecia.\n\nNeutrogena(®), Aveeno(®), and Regaine(®*) will present 12 new scientific\ndata sets at the 35th European Academy of Dermatology and Venereology (EADV)\nCongress taking place September 30(th) through October 3(rd) in Vienna.\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20260930489298/en/\n(https://www.businesswire.com/news/home/20260930489298/en/)\n\nNew Neutrogena science showcased at EADV 2026 in Vienna, Austria\n\nAbstracts presented will share new evidence demonstrating how science-backed\ningredients including niacinamide, trehalose, colloidal oat and 5% minoxidil\ncan help address some of the most common skin and hair concerns consumers\nexperience, including acne, oily skin, dry skin, hyperpigmentation, eczema,\nUV-related skin damage and androgenetic alopecia.\n\nThe findings reinforce a growing body of evidence showing that innovative\nformulations can deliver benefits beyond traditional expectations by helping\nprotect and strengthen the skin barrier, improve visible skin concerns, and\nsupport hair regrowth.\n\nNew Research Advances Understanding of Skin Health, Skin Barrier Function and\nHair Regrowth\n\nConsumers increasingly seek effective, science-backed solutions that address\nmultiple concerns while fitting seamlessly into daily self-care routines.\nResearch from Neutrogena(®), Aveeno(®) and Regaine(®) demonstrates how\ntargeted ingredients can provide measurable benefits for skin and hair health\nwhile supporting confidence and overall well-being.\n\n\"Consumers consistently tell us that healthy skin and healthy hair can have a\nmeaningful impact on their confidence and quality of life,\" said Kate\nStockman, Vice President and Head of EMEA Research & Development at\nKenvue. \"The research we are presenting at EADV advances our understanding of\nhow ingredients such as niacinamide, colloidal oat and 5% minoxidil can\nsupport skin barrier health, improve visible skin concerns and promote hair\nregrowth, respectively. We are proud to continue partnering with the\ndermatology community to advance the science of skin and hair health through\nrigorous research and innovation.\"\n\nNeutrogena(®) Research: Multifunctional Sunscreens Deliver Benefits Beyond UV\nProtection\n\nMultifunctional sunscreen helps manage oily skin and reduce visible\nacne-related signs\n\nConsumers are increasingly seeking sunscreens that deliver cosmetic and skin\nhealth benefits beyond UV protection. New research(i) on Neutrogena(®) Ultra\nSheer Invisible Fluid Sunscreen Oil Control 50+\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neutrogena.co.uk%2Fsuncare%2Fultra-sheer-range%2Foil-control-fluid&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Neutrogena%26%23174%3B+Ultra+Sheer+Invisible+Fluid+Sunscreen+Oil+Control+50%2B&index=1&md5=96dbd6a294babca77b96049f9371aad8)\ndemonstrates how a broad-spectrum sunscreen formulated with 2% trehalose and\n2% niacinamide can help address oily and acne-prone skin while providing daily\nsun protection.\n\nIn two small multi-ethnic Brazilian populations with acne-prone and oily skin,\nresearchers observed:\n\n\n * A 56% reduction in visible redness after 28 days\n\n * A 46% reduction in acne-related hyperpigmentation\n\n * Up to a 12% reduction in skin oiliness\n\n * A 10% reduction in visible shine\n\n * A 13% increase in skin hydration\n\n * High consumer satisfaction, with 90% reporting less skin oiliness and 78%\nreporting reduced acne marks\n\nThese findings demonstrate how multifunctional sunscreen formulations may help\nsupport the appearance of clearer, more balanced skin while protecting against\nUV exposure.\n\nNiacinamide-containing sunscreen improves hydration and helps visibly reduce\nsunspots\n\nA second study(ii) evaluated Neutrogena(®) Ultra Sheer Invisible Fluid\nSunscreen Hydration Fluid 50\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neutrogena.co.uk%2Fsuncare%2Fultra-sheer-range%2Fhydration-fluid&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Neutrogena%26%23174%3B+Ultra+Sheer+Invisible+Fluid+Sunscreen+Hydration+Fluid+50&index=2&md5=37f8ded6949a07059da0674da21afa57)\n, formulated with 2% niacinamide and vitamins C and E, in women with dry skin.\n\nResearchers found that regular use was associated with:\n\n\n * A 22% improvement in skin hydration\n\n * Maintenance of skin barrier integrity\n\n * Significant improvements in skin tone uniformity and radiance\n\n * Reductions in visible facial spot size associated with hyperpigmentation\n\nAfter 28 days of use, more than 90% of participants reported noticing\nincreased skin hydration. Improvements in overall skin tone appearance and\nvisible discoloration continued through 56 days.\n\nAveeno(®) Research: Colloidal Oat Supports Skin Barrier Health, Recovery and\nEczema Care\n\nColloidal oat formulation supports skin recovery following UV-related damage\n\nOat and its concentrated components (avena sativa) have long been recognized\nfor their skin-soothing properties. New research(iii) further demonstrates how\ncolloidal oat can support skin barrier function and recovery following UV\nexposure.\n\nPreclinical and clinical studies evaluating formulations containing the\nAveeno(®)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aveeno.co.uk&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Aveeno%26%23174%3B&index=3&md5=6c8bc66479662703e510ce78b8dcafc0)\nbrand’s proprietary Triple Oat Complex found:\n\n\n * Increased production of key skin barrier proteins, including filaggrin and\nloricrin\n\n * Preservation of these proteins following UV exposure\n\n * Faster skin recovery following application\n\n * Improved hydration and increased ceramide production\n\nTogether, these findings reinforce the important role of colloidal oat in\nsupporting healthy, resilient skin.\n\nDermatologists report benefits of colloidal oat-based emollients alongside\ntopical corticosteroids for eczema\n\nAn international survey(iv) of 178 dermatologists and pediatric clinicians\nacross Germany, Italy, the United Kingdom and the United States evaluated\nperceptions of an Aveeno(®)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.aveeno.co.uk%2F&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Aveeno%26%23174%3B&index=4&md5=8f71e5fba81b027f690d583031082a40)\ncolloidal oat-based emollient used alongside topical corticosteroids in eczema\nmanagement.\n\nAmong respondents:\n\n\n * 87.6% reported frequently recommending a specific colloidal oat-based\nemollient alongside topical corticosteroids\n\n * 92.7% reported observing steroid-sparing or steroid-optimization effects\n\n * Clinicians reported benefits related to skin barrier support, hydration and\nreduced treatment-related concerns\n\nThe findings highlight the perceived value of colloidal oat-based emollients\nas a complementary component of eczema care.\n\nRegaine(®) Research: Earlier Use of 5% Minoxidil Associated with Greater Hair\nRegrowth in Male Androgenetic Alopecia\n\nNew analysis(v) suggests earlier intervention may improve hair regrowth\noutcomes\n\nAndrogenetic alopecia, the most common form of hair loss in men, affects an\nestimated 30% to 50% of men by age 50. New research from Regaine(®) examined\nhow age and stage of hair loss may influence outcomes among men using 5%\nMinoxidil Topical Foam (MTF).\n\nIn a post-hoc analysis of a Phase III clinical trial, researchers assessed\nchanges in non-vellus hair count after 16 weeks of treatment with Regaine(®)\n5% Minoxidil Topical Foam\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.regaine.co.uk%2Fproducts%2Fmens-foam&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Regaine%26%23174%3B+5%25+Minoxidil+Topical+Foam&index=5&md5=201ed0446822afe585b1bc34025ca2c7)\n. The analysis found greater hair regrowth among younger men and among those\nat earlier stages of hair loss based on the Norwood-Hamilton classification\nscale.\n\nKey findings included:\n\n\n * Men aged 20 to 30 years experienced an average increase of 26.25 hairs from\nbaseline after 16 weeks, compared with 19.93 hairs among men older than 30\nyears.\n\n * Men with Type III hair loss experienced an average increase of 23.06 hairs,\ncompared with 18.70 hairs among men with more advanced Type IV and Type V hair\nloss.\n\n * Statistically significant improvements in hair regrowth versus placebo were\nobserved across all hair loss classifications (p<0.002).\n\nThe analysis concluded that while 5% Minoxidil Topical Foam promoted hair\nregrowth across all ages and stages studied, greater regrowth was observed\namong younger men and those at earlier stages of androgenetic alopecia,\nhighlighting the potential value of early intervention.\n\nAdditional Research and Scientific Exchange at EADV 2026\n\nAdditional new studies will further reinforce the research of Neutrogena(®),\nAveeno(®), and Regaine(®) at EADV 2026. Neutrogena(®) will also sponsor an\nindustry session entitled “Raising the Bar-rier: New Hydration Evidence in\nCompromised Skin” including industry experts Ted Lain MD, MBA, FAAD, Patrica\nFarris MD, FAAD, and Kenvue Head of Medical Affairs North America, Skin Health\n& Baby, Asha Patel Shah MD, MBA, FAAD. \n\nFor more information about the research being presented by Neutrogena(®),\nAveeno(®), and Regaine(®) at the 35th EADV Congress, please contact the\nmedia representatives below.\n\n(*)Neutrogena(®), Aveeno(®), and Regaine(®) are brands of Kenvue Brands\nLLC, a subsidiary of Kenvue Inc.\n       \n References \n       \n (i) Rennó I, Felix D, Satake C, et al. Clinical Evidence of Improved Post \n Inflammatory Skin Changes and Skin Oiliness with Continuous Use of a Facial \n Sunscreen Containing 2% Trehalose and 2% Niacinamide in a Multiethnic \n Brazilian Population. Presented at: 35(th) EADV Congress; September 30-October \n 3, 2026; Vienna Austria. \n (ii) Rennó I, Felix D, Moreira G, et al. Additional Therapeutic Benefits of a \n Sunscreen with 2% Niacinamide for Dry Skin: A 56-Day Clinical Study in a \n Brazilian Population. Presented at: 35 EADV; September 30-October 3, 2026; \n Vienna, Austria. \n (iii) Edison BL, Besingi R, Parsa R, et al. Pre-Clinical and Clinical Efficacy \n of an Oat-containing Lotion Demonstrated Increased Protein, Ceramide, Skin \n Resiliency and Speed of Healing the Skin Barrier. Presented at: 35th EADV \n Congress; September 30-October 3, 2026; Vienna, Austria. \n (iv) Peer A, Ahmad AHH, Lisante TA, Pringle L. Clinician-Reported Perceptions \n of a Colloidal Oat-Based Emollient Used with Topical Corticosteroids in \n Eczema: Results of a Multinational SERMO Survey. Presented at: 35 EADV \n Congress; September 30-October 3, 2026; Vienna, Austria. \n (v) Waide RJ, McGuire JA, LaTerra P, Shah AP. Early Intervention of 5% \n Minoxidil Usage Yields Improved Hair Regrowth in Male Androgenetic Alopecia: \n The Effects of Age and Stage. Presented at: the European Academy of \n Dermatology and Venerology, September 25-28, 2024, Amsterdam, Netherlands. \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930489298/en/\n(https://www.businesswire.com/news/home/20260930489298/en/)\n\nMedia Contacts \n\nEMEA Local Media Contact:\n\nNatalie McCabe\n\nnbuhl@kenvue.com (mailto:nbuhl@kenvue.com)\n\nGlobal R&D Media Relations:\n\nMeghan Harding\n\nMHardin1@kenvue.com (mailto:MHardin1@kenvue.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5rCST0a-20260930","title":"Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair","author":"Business Wire","ticker":"KVUE","created":"2026-09-30T10:45:00.172Z","tickers":["KVUE"],"exchange":"NYSE","article_body":"Neutrogena(®), Aveeno(®), and Regaine(®) Present New Scientific Evidence\nDemonstrating How Science-Backed Ingredients Support Healthy Skin and Hair\n\nResearch shared at the 35th European Academy of Dermatology and Venereology\n(EADV) Congress highlights the benefits of multifunctional sunscreens,\ncolloidal oat formulations addressing acne, hyperpigmentation, eczema,\nUV-related skin damage, and the impact of 5% minoxidil for alopecia.\n\nNeutrogena(®), Aveeno(®), and Regaine(®*) will present 12 new scientific\ndata sets at the 35th European Academy of Dermatology and Venereology (EADV)\nCongress taking place September 30(th) through October 3(rd) in Vienna.\n\nThis press release features multimedia. View the full release here:\nhttps://www.businesswire.com/news/home/20260930489298/en/\n(https://www.businesswire.com/news/home/20260930489298/en/)\n\nNew Neutrogena science showcased at EADV 2026 in Vienna, Austria\n\nAbstracts presented will share new evidence demonstrating how science-backed\ningredients including niacinamide, trehalose, colloidal oat and 5% minoxidil\ncan help address some of the most common skin and hair concerns consumers\nexperience, including acne, oily skin, dry skin, hyperpigmentation, eczema,\nUV-related skin damage and androgenetic alopecia.\n\nThe findings reinforce a growing body of evidence showing that innovative\nformulations can deliver benefits beyond traditional expectations by helping\nprotect and strengthen the skin barrier, improve visible skin concerns, and\nsupport hair regrowth.\n\nNew Research Advances Understanding of Skin Health, Skin Barrier Function and\nHair Regrowth\n\nConsumers increasingly seek effective, science-backed solutions that address\nmultiple concerns while fitting seamlessly into daily self-care routines.\nResearch from Neutrogena(®), Aveeno(®) and Regaine(®) demonstrates how\ntargeted ingredients can provide measurable benefits for skin and hair health\nwhile supporting confidence and overall well-being.\n\n\"Consumers consistently tell us that healthy skin and healthy hair can have a\nmeaningful impact on their confidence and quality of life,\" said Kate\nStockman, Vice President and Head of EMEA Research & Development at\nKenvue. \"The research we are presenting at EADV advances our understanding of\nhow ingredients such as niacinamide, colloidal oat and 5% minoxidil can\nsupport skin barrier health, improve visible skin concerns and promote hair\nregrowth, respectively. We are proud to continue partnering with the\ndermatology community to advance the science of skin and hair health through\nrigorous research and innovation.\"\n\nNeutrogena(®) Research: Multifunctional Sunscreens Deliver Benefits Beyond UV\nProtection\n\nMultifunctional sunscreen helps manage oily skin and reduce visible\nacne-related signs\n\nConsumers are increasingly seeking sunscreens that deliver cosmetic and skin\nhealth benefits beyond UV protection. New research(i) on Neutrogena(®) Ultra\nSheer Invisible Fluid Sunscreen Oil Control 50+\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neutrogena.co.uk%2Fsuncare%2Fultra-sheer-range%2Foil-control-fluid&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Neutrogena%26%23174%3B+Ultra+Sheer+Invisible+Fluid+Sunscreen+Oil+Control+50%2B&index=1&md5=96dbd6a294babca77b96049f9371aad8)\ndemonstrates how a broad-spectrum sunscreen formulated with 2% trehalose and\n2% niacinamide can help address oily and acne-prone skin while providing daily\nsun protection.\n\nIn two small multi-ethnic Brazilian populations with acne-prone and oily skin,\nresearchers observed:\n\n\n * A 56% reduction in visible redness after 28 days\n\n * A 46% reduction in acne-related hyperpigmentation\n\n * Up to a 12% reduction in skin oiliness\n\n * A 10% reduction in visible shine\n\n * A 13% increase in skin hydration\n\n * High consumer satisfaction, with 90% reporting less skin oiliness and 78%\nreporting reduced acne marks\n\nThese findings demonstrate how multifunctional sunscreen formulations may help\nsupport the appearance of clearer, more balanced skin while protecting against\nUV exposure.\n\nNiacinamide-containing sunscreen improves hydration and helps visibly reduce\nsunspots\n\nA second study(ii) evaluated Neutrogena(®) Ultra Sheer Invisible Fluid\nSunscreen Hydration Fluid 50\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.neutrogena.co.uk%2Fsuncare%2Fultra-sheer-range%2Fhydration-fluid&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Neutrogena%26%23174%3B+Ultra+Sheer+Invisible+Fluid+Sunscreen+Hydration+Fluid+50&index=2&md5=37f8ded6949a07059da0674da21afa57)\n, formulated with 2% niacinamide and vitamins C and E, in women with dry skin.\n\nResearchers found that regular use was associated with:\n\n\n * A 22% improvement in skin hydration\n\n * Maintenance of skin barrier integrity\n\n * Significant improvements in skin tone uniformity and radiance\n\n * Reductions in visible facial spot size associated with hyperpigmentation\n\nAfter 28 days of use, more than 90% of participants reported noticing\nincreased skin hydration. Improvements in overall skin tone appearance and\nvisible discoloration continued through 56 days.\n\nAveeno(®) Research: Colloidal Oat Supports Skin Barrier Health, Recovery and\nEczema Care\n\nColloidal oat formulation supports skin recovery following UV-related damage\n\nOat and its concentrated components (avena sativa) have long been recognized\nfor their skin-soothing properties. New research(iii) further demonstrates how\ncolloidal oat can support skin barrier function and recovery following UV\nexposure.\n\nPreclinical and clinical studies evaluating formulations containing the\nAveeno(®)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.aveeno.co.uk&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Aveeno%26%23174%3B&index=3&md5=6c8bc66479662703e510ce78b8dcafc0)\nbrand’s proprietary Triple Oat Complex found:\n\n\n * Increased production of key skin barrier proteins, including filaggrin and\nloricrin\n\n * Preservation of these proteins following UV exposure\n\n * Faster skin recovery following application\n\n * Improved hydration and increased ceramide production\n\nTogether, these findings reinforce the important role of colloidal oat in\nsupporting healthy, resilient skin.\n\nDermatologists report benefits of colloidal oat-based emollients alongside\ntopical corticosteroids for eczema\n\nAn international survey(iv) of 178 dermatologists and pediatric clinicians\nacross Germany, Italy, the United Kingdom and the United States evaluated\nperceptions of an Aveeno(®)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.aveeno.co.uk%2F&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Aveeno%26%23174%3B&index=4&md5=8f71e5fba81b027f690d583031082a40)\ncolloidal oat-based emollient used alongside topical corticosteroids in eczema\nmanagement.\n\nAmong respondents:\n\n\n * 87.6% reported frequently recommending a specific colloidal oat-based\nemollient alongside topical corticosteroids\n\n * 92.7% reported observing steroid-sparing or steroid-optimization effects\n\n * Clinicians reported benefits related to skin barrier support, hydration and\nreduced treatment-related concerns\n\nThe findings highlight the perceived value of colloidal oat-based emollients\nas a complementary component of eczema care.\n\nRegaine(®) Research: Earlier Use of 5% Minoxidil Associated with Greater Hair\nRegrowth in Male Androgenetic Alopecia\n\nNew analysis(v) suggests earlier intervention may improve hair regrowth\noutcomes\n\nAndrogenetic alopecia, the most common form of hair loss in men, affects an\nestimated 30% to 50% of men by age 50. New research from Regaine(®) examined\nhow age and stage of hair loss may influence outcomes among men using 5%\nMinoxidil Topical Foam (MTF).\n\nIn a post-hoc analysis of a Phase III clinical trial, researchers assessed\nchanges in non-vellus hair count after 16 weeks of treatment with Regaine(®)\n5% Minoxidil Topical Foam\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.regaine.co.uk%2Fproducts%2Fmens-foam&esheet=54612884&newsitemid=20260930489298&lan=en-US&anchor=Regaine%26%23174%3B+5%25+Minoxidil+Topical+Foam&index=5&md5=201ed0446822afe585b1bc34025ca2c7)\n. The analysis found greater hair regrowth among younger men and among those\nat earlier stages of hair loss based on the Norwood-Hamilton classification\nscale.\n\nKey findings included:\n\n\n * Men aged 20 to 30 years experienced an average increase of 26.25 hairs from\nbaseline after 16 weeks, compared with 19.93 hairs among men older than 30\nyears.\n\n * Men with Type III hair loss experienced an average increase of 23.06 hairs,\ncompared with 18.70 hairs among men with more advanced Type IV and Type V hair\nloss.\n\n * Statistically significant improvements in hair regrowth versus placebo were\nobserved across all hair loss classifications (p<0.002).\n\nThe analysis concluded that while 5% Minoxidil Topical Foam promoted hair\nregrowth across all ages and stages studied, greater regrowth was observed\namong younger men and those at earlier stages of androgenetic alopecia,\nhighlighting the potential value of early intervention.\n\nAdditional Research and Scientific Exchange at EADV 2026\n\nAdditional new studies will further reinforce the research of Neutrogena(®),\nAveeno(®), and Regaine(®) at EADV 2026. Neutrogena(®) will also sponsor an\nindustry session entitled “Raising the Bar-rier: New Hydration Evidence in\nCompromised Skin” including industry experts Ted Lain MD, MBA, FAAD, Patrica\nFarris MD, FAAD, and Kenvue Head of Medical Affairs North America, Skin Health\n& Baby, Asha Patel Shah MD, MBA, FAAD. \n\nFor more information about the research being presented by Neutrogena(®),\nAveeno(®), and Regaine(®) at the 35th EADV Congress, please contact the\nmedia representatives below.\n\n(*)Neutrogena(®), Aveeno(®), and Regaine(®) are brands of Kenvue Brands\nLLC, a subsidiary of Kenvue Inc.\n       \n References \n       \n (i) Rennó I, Felix D, Satake C, et al. Clinical Evidence of Improved Post \n Inflammatory Skin Changes and Skin Oiliness with Continuous Use of a Facial \n Sunscreen Containing 2% Trehalose and 2% Niacinamide in a Multiethnic \n Brazilian Population. Presented at: 35(th) EADV Congress; September 30-October \n 3, 2026; Vienna Austria. \n (ii) Rennó I, Felix D, Moreira G, et al. Additional Therapeutic Benefits of a \n Sunscreen with 2% Niacinamide for Dry Skin: A 56-Day Clinical Study in a \n Brazilian Population. Presented at: 35 EADV; September 30-October 3, 2026; \n Vienna, Austria. \n (iii) Edison BL, Besingi R, Parsa R, et al. Pre-Clinical and Clinical Efficacy \n of an Oat-containing Lotion Demonstrated Increased Protein, Ceramide, Skin \n Resiliency and Speed of Healing the Skin Barrier. Presented at: 35th EADV \n Congress; September 30-October 3, 2026; Vienna, Austria. \n (iv) Peer A, Ahmad AHH, Lisante TA, Pringle L. Clinician-Reported Perceptions \n of a Colloidal Oat-Based Emollient Used with Topical Corticosteroids in \n Eczema: Results of a Multinational SERMO Survey. Presented at: 35 EADV \n Congress; September 30-October 3, 2026; Vienna, Austria. \n (v) Waide RJ, McGuire JA, LaTerra P, Shah AP. Early Intervention of 5% \n Minoxidil Usage Yields Improved Hair Regrowth in Male Androgenetic Alopecia: \n The Effects of Age and Stage. Presented at: the European Academy of \n Dermatology and Venerology, September 25-28, 2024, Amsterdam, Netherlands. \n\n\n \n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930489298/en/\n(https://www.businesswire.com/news/home/20260930489298/en/)\n\nMedia Contacts \n\nEMEA Local Media Contact:\n\nNatalie McCabe\n\nnbuhl@kenvue.com (mailto:nbuhl@kenvue.com)\n\nGlobal R&D Media Relations:\n\nMeghan Harding\n\nMHardin1@kenvue.com (mailto:MHardin1@kenvue.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-30T10:45:00.21957027Z","server_sent_at_ms":1790765100219},"received_at":"2026-09-30T10:45:00.391Z","source_url":"https://www.businesswire.com/news/home/20260930489298/en/"},"analysis":{"id":"145105","press_release_id":"156410","analysis_json":{"industry":{"label":"Personal Care Products","sector":"Consumer Staples"},"redFlags":[],"eventType":"operations_update","narrative":"Kenvue's Neutrogena, Aveeno, and Regaine brands are presenting 12 new scientific data sets at the 35th EADV Congress in Vienna, September 30 through October 3.\n\nKey findings include a Neutrogena niacinamide/trehalose sunscreen showing 56% reduction in visible redness and 46% reduction in acne hyperpigmentation, plus Regaine data indicating earlier 5% minoxidil use yields greater hair regrowth.\n\nThe research supports marketing claims for Kenvue's skin health and hair care portfolio but carries no immediate financial or regulatory impact.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Science-backed brand reinforcement for Kenvue's skin health portfolio at EADV -- supportive but low-impact."},"keyFigures":{"customDimensions":{"datasets_presented":12,"redness_reduction_pct":"56%","dermatologists_surveyed":178,"hydration_improvement_pct":"22%","hyperpigmentation_reduction_pct":"46%","minoxidil_hair_increase_older_men":19.93,"minoxidil_hair_increase_younger_men":26.25}},"quotedText":"Consumers consistently tell us that healthy skin and healthy hair can have a meaningful impact on their confidence and quality of life","namedEntities":{"people":[{"name":"Kate Stockman","role":"VP and Head of EMEA Research & Development, Kenvue"},{"name":"Asha Patel Shah","role":"Head of Medical Affairs North America, Skin Health & Baby, Kenvue"},{"name":"Ted Lain","role":"dermatologist, industry session expert"},{"name":"Patrica Farris","role":"dermatologist, industry session expert"}],"products":["Neutrogena Ultra Sheer Invisible Fluid Sunscreen Oil Control 50+","Neutrogena Ultra Sheer Invisible Fluid Sunscreen Hydration Fluid 50","Aveeno Triple Oat Complex","Regaine 5% Minoxidil Topical Foam"],"companies":[{"name":"Kenvue Inc.","ticker":"KVUE","relationship":"filer/parent company"},{"name":"Kenvue Brands LLC","relationship":"subsidiary"},{"name":"European Academy of Dermatology and Venereology (EADV)","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine scientific-evidence showcase at a dermatology congress supporting Kenvue's consumer brands. No new financials, guidance, or regulatory events; supportive marketing/brand science only."},"tickerRelevance":{"others":[],"primary":"KVUE"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"routine-marketing-science","householdBrandBoost":"Neutrogena/Aveeno household names","financialMateriality":"none"}},"event_type":"operations_update","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":1,"narrative":"Kenvue's Neutrogena, Aveeno, and Regaine brands are presenting 12 new scientific data sets at the 35th EADV Congress in Vienna, September 30 through October 3.\n\nKey findings include a Neutrogena niacinamide/trehalose sunscreen showing 56% reduction in visible redness and 46% reduction in acne hyperpigmentation, plus Regaine data indicating earlier 5% minoxidil use yields greater hair regrowth.\n\nThe research supports marketing claims for Kenvue's skin health and hair care portfolio but carries no immediate financial or regulatory impact.","key_figures":{"customDimensions":{"datasets_presented":12,"redness_reduction_pct":"56%","dermatologists_surveyed":178,"hydration_improvement_pct":"22%","hyperpigmentation_reduction_pct":"46%","minoxidil_hair_increase_older_men":19.93,"minoxidil_hair_increase_younger_men":26.25}},"named_entities":{"people":[{"name":"Kate Stockman","role":"VP and Head of EMEA Research & Development, Kenvue"},{"name":"Asha Patel Shah","role":"Head of Medical Affairs North America, Skin Health & Baby, Kenvue"},{"name":"Ted Lain","role":"dermatologist, industry session expert"},{"name":"Patrica Farris","role":"dermatologist, industry session expert"}],"products":["Neutrogena Ultra Sheer Invisible Fluid Sunscreen Oil Control 50+","Neutrogena Ultra Sheer Invisible Fluid Sunscreen Hydration Fluid 50","Aveeno Triple Oat Complex","Regaine 5% Minoxidil Topical Foam"],"companies":[{"name":"Kenvue Inc.","ticker":"KVUE","relationship":"filer/parent company"},{"name":"Kenvue Brands LLC","relationship":"subsidiary"},{"name":"European Academy of Dermatology and Venereology (EADV)","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T10:45:06.373Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"large-cap","eventGravity":"routine-marketing-science","householdBrandBoost":"Neutrogena/Aveeno household names","financialMateriality":"none"}},"durationMs":5947,"modelName":"glm-5.3-flashx"}}